An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.
作者信息
Ader Florence
出版信息
Clin Microbiol Infect. 2022 Sep;28(9):1293-1296. doi: 10.1016/j.cmi.2022.04.016. Epub 2022 May 7.
Abstract
摘要
相似文献
1
An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.洛匹那韦与利托那韦、洛匹那韦与利托那韦加干扰素-β-1a以及羟氯喹对新冠肺炎住院患者疗效的开放标签随机对照试验：最终结果
Clin Microbiol Infect. 2022 Sep;28(9):1293-1296. doi: 10.1016/j.cmi.2022.04.016. Epub 2022 May 7.
2
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.一项关于洛匹那韦/利托那韦、洛匹那韦/利托那韦联合 IFN-β-1a 和羟氯喹对 COVID-19 住院患者疗效的开放性随机对照试验。
Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26.
3
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.干扰素 β1a 对比干扰素 β1b 和常规治疗方案治疗中重度 COVID-19 成人患者的效果：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):473. doi: 10.1186/s13063-020-04382-3.
4
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.高剂量干扰素β-1a与低剂量干扰素β-1a（基础治疗方案）相比对中度至重度COVID-19的有益效果研究：一项随机对照试验研究方案的结构化总结
Trials. 2020 Oct 26;21(1):880. doi: 10.1186/s13063-020-04812-2.
5
Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.基于干扰素的联合疗法对 COVID-19 危重症患者的抗病毒活性：初步观察
J Glob Antimicrob Resist. 2021 Mar;24:124-126. doi: 10.1016/j.jgar.2020.12.011. Epub 2020 Dec 29.
6
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.一项干扰素 β-1a 治疗重症 COVID-19 的疗效和安全性的随机临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01061-20.
7
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.乌米芬诺韦治疗住院的中重度新型冠状病毒肺炎患者：一项随机临床试验。
Int Immunopharmacol. 2021 Oct;99:107969. doi: 10.1016/j.intimp.2021.107969. Epub 2021 Jul 10.
8
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.皮下注射干扰素 β-1a 治疗 COVID-19：一项非对照前瞻性试验。
Int Immunopharmacol. 2020 Aug;85:106688. doi: 10.1016/j.intimp.2020.106688. Epub 2020 Jun 7.
9
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.比较阿扎那韦/利托那韦/度鲁特韦/羟氯喹与洛匹那韦/利托那韦/羟氯喹治疗方案在 COVID-19 患者中的疗效。
J Med Virol. 2021 Dec;93(12):6557-6565. doi: 10.1002/jmv.27195. Epub 2021 Jul 28.
10
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.洛匹那韦利托那韦和羟氯喹治疗 COVID-19 重症患者：REMAP-CAP 随机对照试验。
Intensive Care Med. 2021 Aug;47(8):867-886. doi: 10.1007/s00134-021-06448-5. Epub 2021 Jul 12.
引用本文的文献
1
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.伊维菌素、氯喹/羟氯喹及阿奇霉素治疗新冠肺炎的疗效：III期临床试验的系统评价
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
2
Immunity and Coagulation in COVID-19.新型冠状病毒肺炎中的免疫与凝血。
Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267.
3
Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients.羟氯喹啉和阿奇霉素早期治疗后的结果：对30423例COVID-19患者数据库的分析。
New Microbes New Infect. 2023 Oct 30;55:101188. doi: 10.1016/j.nmni.2023.101188. eCollection 2023 Oct.
4
Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response.吲哚美辛通过同时抑制病毒复制和炎症反应来对抗全冠状病毒感染。
iScience. 2023 Aug 16;26(9):107631. doi: 10.1016/j.isci.2023.107631. eCollection 2023 Sep 15.
5
Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?新冠疫情中的干扰素：错失在III期临床试验中证明疗效的机会？
Front Med (Lausanne). 2023 May 30;10:1198576. doi: 10.3389/fmed.2023.1198576. eCollection 2023.
本文引用的文献
1
Specialized interferon action in COVID-19.新冠病毒中的干扰素作用机制。
Proc Natl Acad Sci U S A. 2022 Mar 15;119(11). doi: 10.1073/pnas.2116730119.
2
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.一项关于洛匹那韦/利托那韦、洛匹那韦/利托那韦联合 IFN-β-1a 和羟氯喹对 COVID-19 住院患者疗效的开放性随机对照试验。
Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26.
3
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.严重 COVID-19 患者的 I 型干扰素活性和炎症反应受损。
Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13.
Zotero 插件